TY - JOUR
T1 - Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
AU - Moore, Amanda M.
AU - Nooruddin, Zohra
AU - Reveles, Kelly R.
AU - Koeller, Jim M.
AU - Whitehead, Jennifer M.
AU - Franklin, Kathleen
AU - Datta, Paromita
AU - Alkadimi, Munaf
AU - Brannman, Lance
AU - Cotarla, Ion
AU - Frankart, Andrew J.
AU - Mulrooney, Tiernan
AU - Jones, Xavier
AU - Frei, Christopher R.
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press.
PY - 2023/9
Y1 - 2023/9
N2 - Background: Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patterns differed by race in patients with unresectable stage III NSCLC in a Veterans Health Administration (VHA) population. Materials and Methods: This was a retrospective analysis of White and Black adults with unresectable stage III NSCLC treated with durvalumab presenting to any VHA facility in the US from January 1, 2017, to June 30, 2020. Data captured included baseline characteristics and durvalumab treatment patterns, including treatment initiation delay (TID), interruption (TI), and discontinuation (TD); defined as CRT completion to durvalumab initiation greater than 42 days, greater than 28 days between durvalumab infusions, and more than 28 days from the last durvalumab dose with no new durvalumab restarts, respectively. The number of doses, duration of therapy, and adverse events were also collected. Results: A total of 924 patients were included in this study (White = 726; Black = 198). Race was not a significant factor in a multivariate logistic regression model for TID (OR, 1.39; 95% CI, 0.81-2.37), TI (OR, 1.58; 95% CI, 0.90-2.76), or TD (OR, 0.84; 95% CI, 0.50-1.38). There were also no significant differences in median (interquartile range [IQR]) number of doses (White: 15 [7-24], Black: 18 [7-25]; P =. 25) or median (IQR) duration of therapy (White: 8.7 months [2.9-11.8], Black: 9.8 months [3.6-12.0]; P =. 08), although Black patients were less likely to experience an immune-related adverse event (28% vs. 36%, P =. 03) and less likely to experience pneumonitis (7% vs. 14%, P <. 01). Conclusion: Race was not found to be linked with TID, TI, or TD in this real-world study of patients with unresectable stage III NSCLC treated with durvalumab at the VHA.
AB - Background: Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patterns differed by race in patients with unresectable stage III NSCLC in a Veterans Health Administration (VHA) population. Materials and Methods: This was a retrospective analysis of White and Black adults with unresectable stage III NSCLC treated with durvalumab presenting to any VHA facility in the US from January 1, 2017, to June 30, 2020. Data captured included baseline characteristics and durvalumab treatment patterns, including treatment initiation delay (TID), interruption (TI), and discontinuation (TD); defined as CRT completion to durvalumab initiation greater than 42 days, greater than 28 days between durvalumab infusions, and more than 28 days from the last durvalumab dose with no new durvalumab restarts, respectively. The number of doses, duration of therapy, and adverse events were also collected. Results: A total of 924 patients were included in this study (White = 726; Black = 198). Race was not a significant factor in a multivariate logistic regression model for TID (OR, 1.39; 95% CI, 0.81-2.37), TI (OR, 1.58; 95% CI, 0.90-2.76), or TD (OR, 0.84; 95% CI, 0.50-1.38). There were also no significant differences in median (interquartile range [IQR]) number of doses (White: 15 [7-24], Black: 18 [7-25]; P =. 25) or median (IQR) duration of therapy (White: 8.7 months [2.9-11.8], Black: 9.8 months [3.6-12.0]; P =. 08), although Black patients were less likely to experience an immune-related adverse event (28% vs. 36%, P =. 03) and less likely to experience pneumonitis (7% vs. 14%, P <. 01). Conclusion: Race was not found to be linked with TID, TI, or TD in this real-world study of patients with unresectable stage III NSCLC treated with durvalumab at the VHA.
KW - durvalumab
KW - health disparity
KW - health equity
KW - immunotherapy
KW - lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85170294967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170294967&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyad172
DO - 10.1093/oncolo/oyad172
M3 - Article
C2 - 37335901
AN - SCOPUS:85170294967
SN - 1083-7159
VL - 28
SP - 804
EP - 811
JO - Oncologist
JF - Oncologist
IS - 9
ER -